Kiadis receives $9.5 million from the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program to fund Kiadis K-NK cell COVID-19 therapy

by NASDAQ Market News September 15, 2020

NASDAQ Market News
Click here to email author

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells

Data Science Impacting the Pharmaceutical Industry, 2020 Report – Accelerating COVID-19 Drug Discovery with AI and Data Science

Ads